Pear Therapeutics Inc

Pear Therapeutics — Investor Presentation (January 2022)

45 slides from Pear Therapeutics's investor presentation, Jan 11, 2022

  1. Slide 1: Software-based Medicines for the Treatment of Serious Disease

    1 Software-based Medicines for the Treatment of Serious Disease Prescription Digital Therapeutics Investor Presentation January 2022 Copyright 2022, Pear Therapeutics, Inc. All rights reserved.

  2. Slide 2: Safe Harbor Statements

    2 Safe Harbor Statements Forward-Looking Statements and other Cautions/Industry and Market Data Unless the context indicates otherwise, the terms “Pear,” “Company,” “we,” “us,” and “our” refer to Pear Therapeutics, Inc. This presentation contains forward-looking statements within the meaning of the

  3. Slide 3: Pear is the leader in software-based medicines, called PDTs

    Pear is the leader in software- based medicines, called PDTs 3 E M E R G I N G S E C T O R O F S O F T W A R E - B A S E D M E D I C I N E S We believe Prescription Digital Therapeutics (PDTs) could become first-line treatment for most conditions, disrupting the >$3T global healthcare industry1 P E

  4. Slide 4: Contents

    The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Products and Clinical Data Commercial Product Deployment Long-term Strategy and Opportunity 2022 Milestones and Execution 4 Contents Appendix

  5. Slide 5: Major trends converge to highlight a need for software-based medicines

    5 Major trends converge to highlight a need for software- based medicines Number of people who have used telehealth doubled, from 39.4% pre-COVID-19 to 79.5% post-quarantine2 T R A N S I T I O N T O T E L E M E D I C I N E Americans spend an average of 5.4 hours on their mobile phones daily as big d

  6. Slide 6: PDTs are software-based medicines to treat serious disease

    6 1900+ 1980+ 2000+ 2020+ Small Molecules Biologics Cell/Gene Therapies Prescription Digital Therapeutics HEALTH AND WELLNESS APPS PHARMACEUTICALS PRESCRIPTION DIGITAL THERAPEUTICS Utilizes digital technology to improve human health Tested in randomized controlled trials FDA authorized safe and effe

  7. Slide 7: PDTs are poised to disrupt care delivery

    7 24/7 remote access without fear of stigma Favorable side effect profile vs medications Reduce overall healthcare costs Fill gaps in care across large populations Improve reach allowing for broader patient impact Reimbursable events for dashboard interactions PDTs are poised to disrupt care deliver

  8. Slide 8: Pear Products and/or Pipeline

    8 Pear Products and/or Pipeline I N D I C A T I O N S W I T H F D A - A U T H O R I Z E D P D T s 1 - 2 C O M M E R C I A L P R O D U C T S • Substance use disorder • Opioid use disorder • Chronic insomnia • ADHD • Inflammatory bowel syndrome • Amblyopia • Chronic pain • PTSD (Nightmare Disorder) P

  9. Slide 9: Contents

    The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Products and Clinical Data Commercial Product Deployment Long-term Strategy and Opportunity 2022 Milestones and Execution 9 Contents Appendix

  10. Slide 10: Pear Therapeutics is the category creator and leader in PDTs

    10 Pear Therapeutics is the category creator and leader in PDTs Pear is the first mover and leader in PDTs via the first 3 FDA-authorized products P E A R I S A P I O N E E R1 *As of July 2021, Pear’s only Ex-US authorization is Singapore for reSET with plans to expand to other Ex-US markets. FDA-au

  11. Slide 11: Pear's team and culture are a unique mix of life science and tech

    11 Pear’s team and culture are a unique mix of life science and tech person tech + healthcare team in Boston, San Francisco, and Raleigh 300+ M A N A G E M E N T COREY MCCANN, MD, PHD President & CEO CHRIS GUIFFRE, JD, MBA CFO & COO ERIN BRENNER Chief Product Development Officer KATHY JEFFERY Chief

  12. Slide 12: Pear is focused on commercialization and development of PDTs at scale

    F D A A U T H O R I Z E D P R O D U C T S 14 100+3 P R O D U C T C A N D I D A T E S I N P I P E L I N E P R O D U C T O P P O R T U N I T I E S L E V E R A G I N G P L A T F O R M 12 Pear is focused on commercialization and development of PDTs at scale

  13. Slide 13: Pear's first three commercial products are designed to redefine care

    13 $5B+ T O T A L A D D R E S S A B L E M A R K E T ( U S ) 1 $1B+ $5B+ Only product FDA authorized to treat addiction to alcohol, cannabis, cocaine and stimulants Only FDA-authorized software product that’s proven to help patients with opioid use disorder stay in outpatient treatment longer Only FD

  14. Slide 14: Pear has a robust pipeline of product candidates

    14 Substance Use Disorder Opioid Use Disorder Chronic Insomnia Alcohol Use Disorder Schizophrenia Anxiety (GAD) Depression (MDD) Bipolar PTSD Acute and Chronic Pain Migraine Multiple Sclerosis Epilepsy IBS Specialty GI Oncology Cardiovascular Discovery POC Pivotal Commercial P R O D U C T N A M E O

  15. Slide 15: Our dual platform enables discovery, development, and commercialization of PDTs

    15 Multi-product clinician dashboard Patient service center and specialty pharmacy Data infrastructure and access to claims data Telemedicine integration and field salesforce Modular payor contracts and adjudication of value-based agreements Component library of therapeutics and biomarkers In-licens

  16. Slide 16: Contents

    The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Products and Clinical Data Commercial Product Deployment Long-term Strategy and Opportunity 2022 Milestones and Execution 16 Contents Appendix

  17. Slide 17: reSET and reSET-O FDA-authorized products

    17 First-ever PDT to receive Breakthrough Designation FDA-authorized for use in combination with buprenorphine to treat 2M+ Americans suffering from addiction to opiates4 3 successful RCTs in >450 opioid use disorder (OUD) patients: 2 with reSET-O + buprenorphine and 1 with reSET-O + methadone5-8 an

  18. Slide 18: reSET and reSET-O patient and clinician platform

    18 Rapid insights into patient engagement and practice performance via single-secure platform • Cognitive Behavioral Therapy (CBT) • Fluency Training • Contingency Management • Craving & Trigger Assessment • Real-World Engagement • Concept proficiency • Cravings & Triggers • Urine Drug Screens & App

  19. Slide 19: Clinical trial and real-world results

    19 85% of patients abstinent at 12 weeks588% of patients retained in therapy at 12 weeks5 62% reduction in inpatient hospital utilization at 6 months6* 20% reduction in emergency department visits at 6 months6* improved abstinence for reSET1>2X 82% 100% Up to 12 months Up to of patients retained in

  20. Slide 20: Somryst FDA-authorized for chronic insomnia

    20 FDA-authorized to treat patients with chronic insomnia Examined in 29 completed or ongoing studies Delivers drug-free treatment without the risk of dependence and inappropriate long-term use Addresses supply-demand mismatch in insomnia care (<300 CBT-I accredited providers for >30M Americans1-2)

  21. Slide 21: Somryst clinical and real-world data

    21 C L I N I C A L R E A L W O R L D Health economic data expected in 1H 2022 Decrease in the severity of insomnia symptoms145% Decrease in depression symptoms2>50% Durable effect on insomnia, depression, and anxiety3-418 MONTHS Up to Decrease in the severity of insomnia symptoms5 Decrease in the ti

  22. Slide 22: Contents

    The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Products and Clinical Data Commercial Product Deployment Long-term Strategy and Opportunity 2022 Milestones and Execution 22 Contents Appendix

  23. Slide 23: Commercial strategy leverages real-world clinical data to drive coverage

    23 Additional patients treated enhances RWE and HEOR data Our commercial strategy leverages real- world clinical data to drive coverage Data-driven product enhancements Evolving payor value proposition Coverage decisions drive additional prescribing REAL-WORLD DATA + ADVOCACY 02 OPTIMIZED PRODUCTS03

  24. Slide 24: Prescriptions and prescribers

    24 20,000+ prescriptions 700+ prescribers 65% of prescriptions in states most impacted by opioid epidemic.1 82% of providers were very satisfied or somewhat satisfied with their overall performance2* States with a prescription Prescribing institutions and have demonstrated national prescriber tracti

  25. Slide 25: Formulary placement and coverage

    25 and have achieved formulary placement and coverage PBMs Available on formulary without prior authorization for 2 of top 5 PBMs COMMERCIAL PAYORS Covered benefit for employees across multiple Fortune 500 companies and Regional Payors STATE PAYORS Covered for all Medicaid patients in MA FEDERAL PAY

  26. Slide 26: Real-world healthcare cost reductions

    26 has demonstrated real-world healthcare cost reductions Setting of care Cost/patient reSET-O (n=444) Cost/patient Control (n=64) Difference (Control minus reSET-O) Facility Services $2,693 $6,130 ($3,437) Clinician services $6,040 $5,311 $729 Net Cost Difference ($2,708)1 46% reduction in hospital

  27. Slide 27: Contents

    The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Products and Clinical Data Commercial Product Deployment Long-term Strategy and Opportunity 2022 Milestones and Execution 27 Contents Appendix

  28. Slide 28: Pear's PDT engine is product commercialization at scale

    28 P E A R C R E A T E P E A R C O N N E C T 925 ASSETS EVALUATED* OPPORTUNITIES FOR ACQUISITION OR IN-LICENSING COMPLETED DEALS 132 18 Pear’s PDT engine is product commercialization at scale A C Q U I S I T I O N E N G I N E D I S C O V E R Y D E V E L O P M E N T *925 assets evaluated since 2018.

  29. Slide 29: Pear's first-mover advantage and competitive advantages

    29 Foundational estate including 20+ owned and licensed patents I P Payor and provider integration P L A T F O R M Products improve over time with more data D A T A Pathway requires clinical evidence R E G U L A T O R Y Pear’s first- mover advantage is bolstered by competitive advantages leveraged b

  30. Slide 30: Pear is the category leader for PDTs

    30 • Developed by Pear and other companies • Mono therapies and drug/software combos PDTs for a wide range of Medical Conditions • Comprehensive suite of offerings across disease states • Cross-prescribing via multi- product clinician dashboard • Data systems integration underway for payors and prov

  31. Slide 31: Pear is poised to capture massive economic value

    31 Pear is poised to capture massive economic value PDTs as treatment for a wide range of medical conditions represent a total addressable market opportunity in the U.S. $250B+ Pear is the category creator and market leader with a serviceable available market from current products in the U.S. $2B+ P

  32. Slide 32: Contents

    The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Products and Clinical Data Commercial Product Deployment Long-term Strategy and Opportunity 2022 Milestones and Execution 32 Contents Appendix

  33. Slide 33: Multiple near-term value creation milestones

    33 P I P E L I N E Additional PDT candidates and digital biomarker licenses/acquisitions Clinical data in Alcohol Use Disorder, Depression, Anxiety, Schizophrenia Data from drug / software combos & drug-dose optimization 6-month HEOR data 6-month HEOR data Adoption by large healthcare providers Cove

  34. Slide 34: Pear is poised for near-term commercial scale

    34 WHERE WE ARE TODAY PROJECTED YE 2023 Pear is poised for near-term commercial scale Product candidates in pivotal studies3 Prescriptions in 2023>150K Projected revenue$125M Product candidates20 12 Month HEOR data for reSET, reSET-O, and Somryst Covered lives>100M S C R I P T V O L U M E • Deeper i

  35. Slide 35: Commercial product ramp through 2023

    35 Commercial product ramp through 2023 Previously Projected YE 2021 Actual 2021 Projected YE 2022 Projected YE 2023 Total Rx (product mix) ~12,500 Predominantly reSET and reSET-O To Be Reported March ‘22 ~50K-60K Somryst begins to ramp ~150K-190K Nearing steady state across products • Prescribing e

  36. Slide 36: Contents

    The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Products and Clinical Data Commercial Product Deployment Long-term Strategy and Opportunity 2022 Milestones and Execution 36 Contents Appendix

  37. Slide 37: Top-line outcomes from the reSET Pivotal Trial

    37 Top-line outcomes from the reSET Pivotal Trial HIGHLIGHTS CLINICAL OUTCOMES SUMMARY FROM 12-WEEK PIVOTAL TRIAL1 Abstinence Among patients whose primary addiction was not opioids, in a secondary analysis, adding reSET to treatment as usual (TAU) more than doubled abstinence rates (40.3% vs 17.6%)

  38. Slide 38: reSET-O pivotal trial outcomes

    38 Patients retained at 12-week end point 82.4% 68.4% P=.0224 TAU + reSET-O (n=91) TAU (n=79) T R E A T M E N T R E T E N T I O N R A T E 77.3% 62.1%TAU (n=79) TAU* + reSET-O (n=91) P=.02 A B S T I N E N C E R A T E S B Y T R E A T M E N T G R O U P A b st in en ce HIGHLIGHTS CLINICAL OUTCOMES SUMMA

  39. Slide 39: reSET-O real world outcomes

    39 real world outcomes Analyses of “Abstinence” for each group: * Missing Data Removed: No positive UDS and/or self-reported use over the final 4 weeks of the 12-week reSET-O® prescription (weeks 9-12); Patients without any data (UDS or self-reports) over the final four weeks removed from analysis p

  40. Slide 40: Somryst pivotal trial outcomes

    40 pivotal trial outcomes 0 5 10 15 20 Baseline End of Treatment (Week 9) 6 months follow up 12 months follow up ↓51% ↓57% Mean Insomnia Severity Index Score by Treatment Group (N=303) *P<0.0001 Difference between treatment groups at all times after baseline ↓45% ↓18% ↓32% ↓35% Sub-threshold for cli

  41. Slide 41: Somryst patient engagement in the real world

    41 patient engagement in the real world 19 18 15 13 11 10 0 5 10 15 20 C1 C2 C3 C4 C5 C6 IS I S co re ISI Score • 7,414 patients utilized Somryst in a pre-commercial pilot study1-3 • Patients utilized the product for 9 weeks, consisting of 6 treatment modules (cores) • Data collected: o FDA-reviewed

  42. Slide 42: References

    42 Slide 3 1. https://www.cnbc.com/2017/01/17/tech-set-to-transform-3-trillion-health-care-industry.html Slide 5 1. https://www.cdc.gov/chronicdisease/about/costs/index.htm 2. https://azbigmedia.com/business/future-of-telehealth-is-brighter-than-ever-in-the-wake-of-covid-19/ 3. https://www.aamc.org/

  43. Slide 43: References

    43 Slide 19 1. Campbell et al., American Journal of Psychiatry. 2014. 171(6):683-690. 2. Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964-972. doi:10.1037/a0037496. 3.

  44. Slide 44: References

    44 Slide 37 1. Campbell et al., American Journal of Psychiatry. 2014. 171(6):683-690. Slide 38 1. Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964-972. doi:10.1037/a00

  45. Slide 45: Copyright 2022, Pear Therapeutics, Inc. All rights reserved.

    45 Copyright 2022, Pear Therapeutics, Inc. All rights reserved.

Pear Therapeutics — Investor Presentation (January 2022) on 6ix